Flesinoksan (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Flesinoksan" in Serbian language version.

refsWebsite

Global rank Serbian rank

8nih.gov

4^th place

8^th place

8doi.org

2^nd place

4^th place

2archive.org

6^th place

5^th place

2elsevier.com

610^th place

653^rd place

1archive.today

14^th place

22^nd place

1wiley.com

222^nd place

155^th place

archive.org

Schoeffter P, Hoyer D (1988). „Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus.”. Br J Pharmacol. 95 (3): 975—985. PMC 1854240 . PMID 3207999.
van Hest A, van Drimmelen M, Olivier B (1992). „Flesinoxan shows antidepressant activity in a DRL 72-s screen”. Psychopharmacology. 107 (4): 474—9. PMID 1351303. doi:10.1007/BF02245258.

archive.today

Marc Ansseau; William Pitchot; Antonio Gonzalez Moreno; Jacques Wauthy; Patrick Papart (2004). „Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature.”. Human Psychopharmacology: Clinical and Experimental. 8 (4): 279—283. doi:10.1002/hup.470080407. Архивирано из оригинала 17. 12. 2012. г. Приступљено 07. 10. 2012.

doi.org

Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology. 14 (2): 151—5. PMID 15013031. doi:10.1016/S0924-977X(03)00108-1.
Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C (1995). „Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study”. Neuropharmacology. 34 (10): 1311—26. PMID 8570029. doi:10.1016/0028-3908(95)00098-Q.
Wouters W, Tulp MT, Bevan P (1988). „Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors”. European Journal of Pharmacology. 149 (3): 213—23. PMID 2842163. doi:10.1016/0014-2999(88)90651-6.
van Hest A, van Drimmelen M, Olivier B (1992). „Flesinoxan shows antidepressant activity in a DRL 72-s screen”. Psychopharmacology. 107 (4): 474—9. PMID 1351303. doi:10.1007/BF02245258.
Rodgers RJ, Cole JC, Davies A (1994). „Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan”. Pharmacology, Biochemistry, and Behavior. 48 (4): 959—63. PMID 7972301. doi:10.1016/0091-3057(94)90205-4.
Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993). „An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression”. International Clinical Psychopharmacology. 8 (3): 167—72. PMID 8263314. doi:10.1097/00004850-199300830-00005.
Marc Ansseau; William Pitchot; Antonio Gonzalez Moreno; Jacques Wauthy; Patrick Papart (2004). „Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature.”. Human Psychopharmacology: Clinical and Experimental. 8 (4): 279—283. doi:10.1002/hup.470080407. Архивирано из оригинала 17. 12. 2012. г. Приступљено 07. 10. 2012.
Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14 (2): 151—5. PMID 15013031. doi:10.1016/S0924-977X(03)00108-1.

elsevier.com

linkinghub.elsevier.com

Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C (1995). „Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study”. Neuropharmacology. 34 (10): 1311—26. PMID 8570029. doi:10.1016/0028-3908(95)00098-Q.
Rodgers RJ, Cole JC, Davies A (1994). „Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan”. Pharmacology, Biochemistry, and Behavior. 48 (4): 959—63. PMID 7972301. doi:10.1016/0091-3057(94)90205-4.

nih.gov

ncbi.nlm.nih.gov

Schoeffter P, Hoyer D (1988). „Centrally acting hypotensive agents with affinity for 5-HT1A binding sites inhibit forskolin-stimulated adenylate cyclase activity in calf hippocampus.”. Br J Pharmacol. 95 (3): 975—985. PMC 1854240 . PMID 3207999.
Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology. 14 (2): 151—5. PMID 15013031. doi:10.1016/S0924-977X(03)00108-1.
Hadrava V, Blier P, Dennis T, Ortemann C, de Montigny C (1995). „Characterization of 5-hydroxytryptamine1A properties of flesinoxan: in vivo electrophysiology and hypothermia study”. Neuropharmacology. 34 (10): 1311—26. PMID 8570029. doi:10.1016/0028-3908(95)00098-Q.
Wouters W, Tulp MT, Bevan P (1988). „Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors”. European Journal of Pharmacology. 149 (3): 213—23. PMID 2842163. doi:10.1016/0014-2999(88)90651-6.
van Hest A, van Drimmelen M, Olivier B (1992). „Flesinoxan shows antidepressant activity in a DRL 72-s screen”. Psychopharmacology. 107 (4): 474—9. PMID 1351303. doi:10.1007/BF02245258.
Rodgers RJ, Cole JC, Davies A (1994). „Antianxiety and behavioral suppressant actions of the novel 5-HT1A receptor agonist, flesinoxan”. Pharmacology, Biochemistry, and Behavior. 48 (4): 959—63. PMID 7972301. doi:10.1016/0091-3057(94)90205-4.
Grof P, Joffe R, Kennedy S, Persad E, Syrotiuk J, Bradford D (1993). „An open study of oral flesinoxan, a 5-HT1A receptor agonist, in treatment-resistant depression”. International Clinical Psychopharmacology. 8 (3): 167—72. PMID 8263314. doi:10.1097/00004850-199300830-00005.
Pitchot W, Wauthy J, Legros JJ, Ansseau M (2004). „Hormonal and temperature responses to flesinoxan in normal volunteers: an antagonist study”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14 (2): 151—5. PMID 15013031. doi:10.1016/S0924-977X(03)00108-1.

wiley.com

www3.interscience.wiley.com

Marc Ansseau; William Pitchot; Antonio Gonzalez Moreno; Jacques Wauthy; Patrick Papart (2004). „Pilot study of flesinoxan, a 5-HT1A agonist, in major depression: Effects on sleep REM latency and body temperature.”. Human Psychopharmacology: Clinical and Experimental. 8 (4): 279—283. doi:10.1002/hup.470080407. Архивирано из оригинала 17. 12. 2012. г. Приступљено 07. 10. 2012.